This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs

MADISON, N.J., April 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sukumar Nagendran, M.D., has joined Quest Diagnostics as vice president, medical affairs, a new position.

In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services. He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the company's headquarters in Madison, NJ.

"Dr. Nagendran has an impressive record of successful medical affairs in several clinical areas as well as in new product and business development and clinical trial operations," said Dr. Cohen. "These experiences, combined with his relationships with top medical and healthcare experts, will help us to engage medical opinion leaders, payers and clients in more productive dialogues about the composition and value of our services. These competencies are critical as our company strives to be more externally focused and responsive to market needs."

Most recently, Dr. Nagendran served as vice president, head of medical affairs at Reata Pharma. Prior to that, he was therapeutic-area head for new product development, medical affairs, clinical operations and biometrics, in which he oversaw several therapeutic areas, including oncology, cardiovascular disease and diabetes, for Daiichi Sankyo. He has held other senior positions related to clinical development and medical affairs for Pfizer and Novartis. 

Dr. Nagendran also has significant clinical practice experience. Early in his career, Dr. Nagendran practiced in a large internal-medicine physician group and was a staff physician at three hospitals in Phoenix, Arizona. In addition, he is formerly a member of the PrimeCare managed care committee for Phoenix-based Banner Health Systems, one of the largest nonprofit healthcare systems in the United States.

Dr. Nagendran's research on cardiovascular disease, diabetes, oncology, pulmonary medicine and other areas of medicine has been published in a number of peer-reviewed publications, including Endocrine Practice, Current Medical Research & Opinion and Journal of Clinical Lipidology.

Dr. Nagendran earned a bachelor's degree in biochemistry from Rutgers University and earned his doctorate in medicine from UMDNJ-Robert Wood Johnson Medical School in New Jersey, where he was given the Robert Wood Johnson Alumni award for outstanding medical student. He completed his internal medicine training at The Mayo Clinic in Rochester, Minn., and was inducted into the prestigious Mayo Alumni Laureate Group.

About Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.

Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs